secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001437749-24-022297
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences receives FDA Breakthrough Device Designation for nsPFA Cardiac Surgery System for AF treatment
--------------------------------------------------------------------------------

- FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System to treat atrial fibrillation.
- Designation provides expedited development and prioritized review; company plans PMA approval pathway.
- Preclinical data shows single <2-second application creates transmural ablation, ~20x faster than thermal RF.
- First-in-human cases expected in Netherlands soon; pivotal clinical trial planned for 2025.
- No risk of thermal spread due to non-thermal nano-PFA mechanism, potentially safer than current options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924022297/0001437749-24-022297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924022297/plse20240708_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer